Literature DB >> 23993191

Immunopathogenic mechanisms of systemic autoimmune disease.

Marie Wahren-Herlenius1, Thomas Dörner.   

Abstract

Systemic lupus erythematosus, Sjögren's syndrome, and dermatomyositis are systemic autoimmune diseases that develop after environmental triggering of genetically susceptible individuals. The precise cellular and molecular mechanisms leading to autoimmune disease, and what factors determine which organs are involved, remain poorly understood. Recent insights into genetic susceptibility now make obvious that environmental triggers often act via cellular pathways containing disease-associated polymorphisms. In the breaking of tolerance, the initiating tissue--including dendritic cells--provides a decisive microenvironment that affects immune-cell differentiation, leading to activation of adaptive immunity. Type 1 interferon produced by innate immune cells has a central role in systemic autoimmunity and activates B cells and T cells. In turn, B-cell-derived autoantibodies stimulate dendritic cells to produce type 1 interferon; thus, a positive feedforward loop is formed that includes both the innate and adaptive systems. New treatments could simultaneously and specifically target several such vital pathways in autoimmunity.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23993191     DOI: 10.1016/S0140-6736(13)60954-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  144 in total

1.  Interferon γ (IFNγ) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses.

Authors:  Barbara Kroczynska; Robert L Rafidi; Beata Majchrzak-Kita; Ewa M Kosciuczuk; Gavin T Blyth; Jacek Jemielity; Zofia Warminska; Diana Saleiro; Swarna Mehrotra; Ahmet Dirim Arslan; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2015-12-08       Impact factor: 5.157

2.  Cross talk between neuroregulatory molecule and monocyte: nerve growth factor activates the inflammasome.

Authors:  Ananya Datta-Mitra; Smriti Kundu-Raychaudhuri; Anupam Mitra; Siba P Raychaudhuri
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

3.  Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis.

Authors:  Laura C Cappelli; Mehmet T Dorak; Maria P Bettinotti; Clifton O Bingham; Ami A Shah
Journal:  Rheumatology (Oxford)       Date:  2019-03-01       Impact factor: 7.580

Review 4.  Orthopedic surgery and its complication in systemic lupus erythematosus.

Authors:  Anselm Mak
Journal:  World J Orthop       Date:  2014-01-18

Review 5.  Genome-wide association studies in Sjögren's syndrome: What do the genes tell us about disease pathogenesis?

Authors:  Peter D Burbelo; Kiran Ambatipudi; Ilias Alevizos
Journal:  Autoimmun Rev       Date:  2014-03-18       Impact factor: 9.754

6.  Myeloid-derived suppressor cells in murine AIDS inhibit B-cell responses in part via soluble mediators including reactive oxygen and nitrogen species, and TGF-β.

Authors:  Jessica L Rastad; William R Green
Journal:  Virology       Date:  2016-09-12       Impact factor: 3.616

Review 7.  The mechanisms and applications of T cell vaccination for autoimmune diseases: a comprehensive review.

Authors:  Xin Huang; Haijing Wu; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

8.  [Sjögren's syndrome].

Authors:  T Witte
Journal:  Z Rheumatol       Date:  2014-02       Impact factor: 1.372

9.  Parasitic infection as a potential therapeutic tool against rheumatoid arthritis.

Authors:  Shadike Apaer; Tuerhongjiang Tuxun; Hai-Zhang Ma; Heng Zhang; Amina Aierken; Abudusalamu Aini; Yu-Peng Li; Ren-Yong Lin; Hao Wen
Journal:  Exp Ther Med       Date:  2016-09-05       Impact factor: 2.447

10.  Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus.

Authors:  Ahmed Nader; Mukul Minocha; Ahmed A Othman
Journal:  Clin Pharmacokinet       Date:  2020-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.